CD8A and neoplasm: The results showed that B13.14.1 TCR-engineered T cells could kill tumor cells in a dose-dependent manner and the killing effect of CD4+ T cells was superior to CD8+ T cells, indicating its dependence on CD4 (Figures 3F, G).